Brazil’s securities regulator has ordered a tender offer for Oncoclínicas shares, with analysts estimating the total outlay at R$ 12–14 billion — roughly double initial projections — as a parallel arbitration threatens to delay execution.

POLICY & MARKETS · SEPTEMBER 12, 2026 · LATIN AMERICA
A unanimous ruling by Brazil’s securities regulator has set in motion what analysts estimate could become the country’s largest-ever capital-markets buyout — and placed the entire financial burden on a single American fund manager that is simultaneously fighting the order in arbitration. The Comissão de Valores Mobiliários (CVM), Brazil’s securities and exchange commission, voted 3–0 on 25 August 2026 to require a public tender offer, known in Brazil as an oferta pública de aquisição de ações (OPA), for the shares of Oncoclínicas (B3: ONCO3), the country’s largest cancer-treatment network with 144 units across 47 cities, according to Folha de S.Paulo.
The decision overruled the CVM’s own technical staff, which had twice recommended against requiring the offer, per Folha. The regulator determined that Centaurus Capital, a US-based fund manager whose vehicle Josephina III holds a stake in Oncoclínicas, crossed the 15% ownership threshold that triggers the company’s statutory tag-along clause — an obligation requiring any investor surpassing that level after the initial public offering to extend a purchase offer to all remaining shareholders. Centaurus disputes this reading, arguing it was already present in the company before the IPO.
A price that has moved sharply
Specialist calculations commissioned by Valor Econômico place the per-share OPA price at R$ 8.03, against a pre-announcement trading price of R$ 2.08 — a spread that explains the share-price surge of more than 3.4 times during August, from R$ 0.55 to R$ 1.87, before the CVM’s formal ruling, per Valor. The total outlay, once a Selic-rate correction is applied for the period from 4 November 2024 to the offer date, is estimated by specialists at between R$ 12 billion and R$ 14 billion, according to Valor Econômico’s 28 August report — a range that, if confirmed, would represent roughly double the R$ 6.5 billion initially cited when the CVM’s deliberation began. The Selic adjustment alone accounts for a material portion of that upward revision; the CVM board set the correction reference date at 4 November 2024, per Valor.
Oncoclínicas would also stand to receive R$ 1.2 billion in subscription-bonus proceeds as part of the broader transaction structure, according to Valor Econômico, though the mechanics of that inflow have not been detailed in public filings reviewed for this article.
The concentration of numeric estimates in this story is notable: most published figures trace to Valor Econômico’s reporting, which in turn cites specialist calculations prepared at the outlet’s request. No independent primary document — a CVM resolution text, a company filing, or a court order — has been publicly released setting out the final per-share price or the total offer quantum. Readers should treat the R$ 12–14 billion range as analyst-derived, not as a regulator-confirmed figure.
Arbitration as the operative friction
Centaurus has not accepted the CVM’s ruling. On 21 August — before the board voted — Josephina III filed for arbitration at the Câmara de Arbitragem do Mercado (CAM), B3’s market arbitration chamber, naming Latache, the Brazilian fund manager led by Renato Azevedo, as respondent. Latache, which holds a 14.5% stake, led the shareholder campaign that produced the OPA ruling and stands to receive an estimated R$ 1.5 billion from the offer, per Valor Econômico. Centaurus’s position, stated in a note cited by Folha, is that the CAM ‘holds exclusive jurisdiction to resolve this commercial dispute between partners in a publicly listed company’ and that no OPA can proceed while arbitration is active.
Latache’s attorney, Bernardo Costa, contests that framing, arguing the arbitration is a private matter between the two funds and cannot suspend a CVM-ordered market obligation, per Valor. Minority shareholders have begun organising judicially to enforce the offer independently of the arbitration outcome, according to Valor’s sources. The CVM board set a 60-day execution window running from 25 August, placing the offer deadline at approximately 25 October 2026. Whether that deadline holds — or is stayed by a court or the CAM — has not been resolved as of the date of this article.
The counterargument to a clean execution is structural, not merely procedural. Centaurus faces a potential outlay of up to R$ 14 billion on a company that, as of July 2026, had filed for extrajudicial recovery to restructure R$ 5.1 billion in unsecured debt, with only 37% creditor adhesion at the time of filing — the minimum required under Brazilian law to initiate the process, per Exame. The company’s net debt stood at R$ 2.94 billion at end-2025, with leverage at 4.3 times earnings before interest, taxes, depreciation, and amortisation (EBITDA), above the 3.5-times covenant threshold agreed with creditors, according to Exame. A fund compelled to pay a market-clearing price for shares in a company simultaneously negotiating with creditors faces a valuation paradox: the OPA price is set by a statutory formula anchored to a historical date, while the enterprise value implied by the debt restructuring may be materially lower.
The company’s financial deterioration unfolded across several failed rescue attempts. Porto Saúde and Grupo Fleury, the diagnostics group, jointly proposed a R$ 500 million equity injection into a carved-out clinic entity plus R$ 500 million in convertible debentures, but withdrew after their exclusivity window expired in April 2026, per Valor. Mak Capital, a US fund holding 6.3% of Oncoclínicas, subsequently tabled two alternatives — a R$ 500 million convertible debenture or a R$ 150 million drug-procurement loan — neither of which has been confirmed as executed, per Valor. Starboard, another potential restructuring investor, had its proposal rejected in September 2025 after shareholders objected to the approximately 40% stake it sought and the management changes it required, per Valor.
No analyst estimate of Oncoclínicas’ post-restructuring enterprise value has been published in the sources reviewed for this article. The CVM has not publicly released the full text of its 25 August ruling, and the company has not issued a filing specifying the final OPA terms.
What to Watch
- Whether the CAM arbitration panel issues a stay of the OPA before the 25 October 2026 deadline, and how Brazilian courts respond to minority shareholders’ parallel judicial enforcement efforts
- Progress in Oncoclínicas’ extrajudicial recovery: the company had 90 days from the July 2026 filing to reach the creditor-adhesion threshold required for judicial homologation of its restructuring plan
- Any revision to the per-share OPA price once the CVM publishes the formal resolution text, which will set the Selic-corrected reference figure as a matter of public record rather than specialist estimate
The deeper tension embedded in this situation is jurisdictional, not financial. Brazil’s capital-markets framework and its arbitration system are now pulling in opposite directions over the same transaction — the CVM asserting regulatory authority to compel a market-wide offer, the CAM asserting contractual exclusivity over a bilateral dispute. How that conflict resolves will determine not just whether Centaurus writes a cheque, but which forum governs shareholder-protection obligations in Brazilian listed companies when statutory rules and private arbitration clauses collide.
Oncoclínicas OPA: Key Dates & Milestones
Related coverage
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







